News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
582,931 Results
Type
Article (40929)
Company Profile (106)
Press Release (541896)
Section
Business (162109)
Career Advice (2420)
Deals (29608)
Drug Delivery (90)
Drug Development (73436)
Employer Resources (146)
FDA (14314)
Job Trends (13226)
News (285537)
Policy (28293)
Tag
Academia (2607)
Alliances (41301)
Alzheimer's disease (1255)
Approvals (14235)
Artificial intelligence (135)
Bankruptcy (311)
Best Places to Work (10780)
Breast cancer (113)
Cancer (1010)
Cardiovascular disease (95)
Career advice (2034)
Cell therapy (214)
Clinical research (58303)
Collaboration (342)
Compensation (109)
COVID-19 (2484)
C-suite (98)
Data (1034)
Diabetes (145)
Diagnostics (5976)
Drug pricing (84)
Earnings (56717)
Employer resources (133)
Events (95047)
Executive appointments (285)
FDA (14798)
Funding (310)
Gene therapy (171)
GLP-1 (571)
Government (4243)
Healthcare (17939)
Infectious disease (2570)
Inflammatory bowel disease (99)
Interviews (517)
IPO (13089)
Job creations (2794)
Job search strategy (1677)
Layoffs (379)
Legal (6097)
Lung cancer (172)
Manufacturing (148)
Medical device (11866)
Medtech (11870)
Mergers & acquisitions (16576)
Metabolic disorders (391)
Neuroscience (1521)
NextGen Class of 2024 (6171)
Non-profit (4223)
Northern California (1289)
Obesity (218)
Opinion (191)
Patents (94)
People (52367)
Phase I (17842)
Phase II (25625)
Phase III (19673)
Pipeline (441)
Postmarket research (2351)
Preclinical (7271)
Radiopharmaceuticals (222)
Rare diseases (206)
Real estate (4498)
Regulatory (19185)
Research institute (2216)
Resumes & cover letters (356)
Southern California (1166)
Startups (2990)
United States (11679)
Vaccines (520)
Weight loss (168)
Date
Today (65)
Last 7 days (905)
Last 30 days (3277)
Last 365 days (33092)
2024 (29963)
2023 (36920)
2022 (47646)
2021 (51730)
2020 (50407)
2019 (43654)
2018 (32932)
2017 (28794)
2016 (28040)
2015 (32944)
2014 (25117)
2013 (20522)
2012 (21816)
2011 (22737)
2010 (20106)
Location
Africa (765)
Arizona (129)
Asia (34859)
Australia (7002)
California (2850)
Canada (1175)
China (218)
Colorado (130)
Connecticut (126)
Europe (78590)
Florida (410)
Georgia (110)
Illinois (308)
Indiana (185)
Kansas (81)
Maryland (523)
Massachusetts (2176)
Michigan (156)
Minnesota (224)
New Jersey (833)
New York (848)
North Carolina (636)
Northern California (1289)
Ohio (125)
Pennsylvania (736)
South America (1038)
Southern California (1166)
Texas (390)
Utah (86)
Washington State (321)
582,931 Results for "celltrion healthcare formerly known as celltrion".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Celltrion Announces the Acquisition of iQone Healthcare Switzerland, Further Building Its Expertise and Foothold in Europe
November 14, 2024
·
5 min read
Deals
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
Celltrion Group announced that the merger agreement between Celltrion, Inc. and Celltrion Healthcare Co., Ltd. was approved at the extraordinary general meeting of shareholders of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
October 23, 2023
·
5 min read
Press Releases
Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA® (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting
October 30, 2024
·
13 min read
Pharm Country
Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
Celltrion USA announced it will present the two-year results from the extended LIBERTY studies in adult patients with moderately to severely active Crohn’s disease and ulcerative colitis receiving maintenance treatment after infliximab IV induction.
May 17, 2024
·
17 min read
FDA
Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program
August 12, 2024
·
16 min read
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference
Celltrion, Inc. announced the next phase of its strategic transformation from a developer of the world’s first monoclonal antibody biosimilar to an innovative company focused on new drug development at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.
January 10, 2024
·
7 min read
Press Releases
Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary
August 29, 2024
·
11 min read
Press Releases
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
October 15, 2024
·
6 min read
Policy
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
Celltrion USA announced that the company has submitted a Biologics License Application for CT-P39, an interchangeable biosimilar candidate to XOLAIR® to the U.S. Food and Drug Administration.
March 10, 2024
·
5 min read
Policy
Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab)
Celltrion USA announced the submission of Biologics License Application to the U.S. Food and Drug Administration for CT-P47, a biosimilar candidate of the reference product ACTEMRA®.
January 28, 2024
·
4 min read
1 of 58,294
Next
